Prof Overmoyer speaks with ecancer at IMPAKT 2017 about results from a phase II trial of GTX-024, or enobosarm, against androgen-receptor positive breast cancer. She describes how a new generation of androgens expand treatment options for breast cancer patients, and outlines the design and staging of trials with enobosarm.